Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 16:10:1144170.
doi: 10.3389/fmed.2023.1144170. eCollection 2023.

Preeclampsia pathophysiology and adverse outcomes during pregnancy and postpartum

Affiliations
Review

Preeclampsia pathophysiology and adverse outcomes during pregnancy and postpartum

Courtney Bisson et al. Front Med (Lausanne). .

Abstract

Background: Preeclampsia is a disease with far-reaching consequences that extend beyond the immediate postpartum period and have a significant impact later in life. Preeclampsia exerts an effect on most organ systems in the body. These sequelae are mediated in part by the incompletely elucidated pathophysiology of preeclampsia and the associated vascular changes.

Content: Current research focuses on unraveling the pathophysiology of preeclampsia with the goal of implementing accurate screening and treatment modalities based on disease development and progression. Preeclampsia causes significant short- and long-term maternal morbidity and mortality, not only in the cardiovascular system but also in other organ systems throughout the body. This impact persists beyond pregnancy and the immediate postpartum period.

Summary: The goal of this review is to discuss the current understanding of the pathophysiology of preeclampsia as it relates to the adverse health consequences in patients impacted by this disease, along with a brief discussion of ways to improve overall outcomes.

Keywords: hypertension; long-term effect; morbidity; preeclampsia; pregnancy.

PubMed Disclaimer

Conflict of interest statement

SR reports serving as a consultant to Roche Diagnostics and Thermo Fisher Scientific and has received funding from Roche Diagnostics and Siemens for studies related to the use of angiogenic factors in pregnancy which is unrelated to work for this manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Two-staged model of preeclampsia pathogenesis. Stage 1 consists of the preclinical stage and is characterized by abnormal placentation, which leads to the release of soluble factors in maternal circulation, leading to systemic endothelial dysfunction and hypertension (Stage 2).
Figure 2
Figure 2
Organ systems impacted by preeclampsia. The figure shows various organ systems affected by preeclampsia leading to short-term and long-term maternal/fetal morbidity and mortality.

References

    1. CDS . Pregnancy Mortality Surveillance System. Atlanta, GA: CDS; (2022).
    1. No Authors . Gestational Hypertension and Preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. (2020) 135:e237–60. doi: 10.1097/AOG.0000000000003891 - DOI - PubMed
    1. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. (2019) 366:l2381. doi: 10.1136/bmj.l2381 - DOI - PubMed
    1. Bartsch E, Medcalf KE, Park AL, Ray JG, Group HRoP-eI . Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. (2016) 353:i1753. doi: 10.1136/bmj.i1753 - DOI - PMC - PubMed
    1. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. (2019) 124:1094–112. doi: 10.1161/CIRCRESAHA.118.313276 - DOI - PubMed

LinkOut - more resources